

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Medtide Inc.

泰德醫藥(浙江)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3880)

**VOLUNTARY ANNOUNCEMENT
UPDATE ON THE STRATEGIC EXPANSION OF
LARGE-SCALE PEPTIDE CDMO PRODUCTION CAPACITY**

This announcement is made by Medtide Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors of the Company with information on the latest business development and progress of the production capacity layout of the Group.

The board of directors of the Company (the “**Board**”) announces that, to advance the Group’s strategic capacity deployment for its peptide and oligonucleotide CDMO business, the Group has entered into an acquisition agreement in respect of a parcel of industrial land and property located in Qiantang District, Hangzhou City, the relevant acquisition has been completed as of the date of this announcement, and such land and property are proposed to be used as phase I of the Group’s large-scale CDMO production base project (the “**Project**”).

The Project covers a site area of approximately 30 mu, and the existing factory premises thereon have a gross floor area of approximately 13,500 square metres. The Group plans to construct a large-scale peptide active pharmaceutical ingredients production line at the Project, with an estimated designed annual production capacity of 3 to 5 tonnes. However, the actual production capacity and the schedule for production commencement will be subject to factors including project construction, equipment commissioning, regulatory approvals, and market demand. Subsequently, the Group intends to further integrate an adjacent land parcel of approximately 56 mu in phase II to develop a large-scale CDMO production park with a total site area of approximately 86 mu, with a view to further expanding production capacity to meet large-scale demand and enhancing its capability to undertake large-scale commercialization projects.

The Board considers that such capacity expansion is intended to accommodate the business needs of the Group including the development of its peptide and oligonucleotide CDMO business, which is expected to enhance the Group's CDMO service capabilities and capacity to undertake projects, and is in the interests of the Company and its shareholders as a whole.

The subsequent construction progress, timing of production commencement and release of production capacity of the Project are subject to approval, construction, equipment commissioning, market demand and other factors, and therefore involve uncertainties. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board

Medtide Inc.

泰德醫藥(浙江)股份有限公司

Xu Qi

Chairwoman and Chief Executive Officer

Hong Kong, September 24, 2026

As at the date of this announcement, the executive Directors of the Company are Dr. Xu Qi (徐琪), Dr. Li Xiang (李湘), Ms. Li Xiangli (李湘莉) and Ms. Cheng Tao; the non-executive Director of the Company is Mr. Wu Yihui (吳一暉); and the independent non-executive Directors of the Company are Dr. Yu Cheung Hoi (于常海), Dr. Zhu Xun (朱迅) and Mr. Xia Xinsheng (夏心晟).